PUBLISHER: Grand View Research | PRODUCT CODE: 1869957
PUBLISHER: Grand View Research | PRODUCT CODE: 1869957
The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.
Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.
The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.
Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.
In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.
Global Antipsychotic Drugs Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region: